C
Compass Therapeutics Inc.
NASDAQ:CMPX
Compass Therapeutics Inc.
NASDAQ:CMPX
Price:
6.6
USD
6.11%
Market Closed
Market Cap:
$1.2B
Relative Value
The Relative Value of one CMPX stock under the Base Case scenario is 2.76 USD. Compared to the current market price of 6.6 USD, Compass Therapeutics Inc. is Overvalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CMPX
Relative Value
Base Case
2.76
USD
Overvaluation 58%
C
Multiples Across Competitors
CMPX Competitors Multiples
Compass Therapeutics Inc. Competitors
Compass Therapeutics Inc. Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
1.2B USD | 0 | -23.3 | -17.7 | -17.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD | 6.6 | 168.5 | 16.3 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD | 5.6 | 26.6 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD | 10.4 | 33 | 24.3 | 25.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 15.6 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD | 3.9 | 20.2 | 13.5 | 16.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 14 | 32.9 | 56 | 57.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
